Aqueous Vascular Endothelial Growth Factor Levels Are Associated With Serous Macular Detachment Secondary to Branch Retinal Vein Occlusion

Park, Sung Pyo; Ahn, Jae-Min; Mun, Gui Hyeong

doi:10.1097/iae.0b013e3181b9f153

Cited by 47 publications

(33 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several authors have reported that the incidence of SRF among eyes with major BRVO was significantly higher than that among eyes with macular BRVO [15,16], and that the mean vascular leaking area in the retina was larger in BRVO patients with SRF than in patients without SRF [15]. Park et al also showed that the mean aqueous levels of VEGF were significantly higher in BRVO eyes with SRF than in eyes with cystoid ME without additional SRF [15] . Baseline VA of patients with and without SRF in BRVO and CRVO patients did not differ significantly in our study.…”

Section: Discussionmentioning

confidence: 94%

“…Some authors have postulated an insufficient draining function of the RPE, which might be due to damage to the RPE cells or a very fast fluid accumulation that exceeds the fluid transport capacity of the retinal pigment epithelium [11,14]. Several authors have reported that the incidence of SRF among eyes with major BRVO was significantly higher than that among eyes with macular BRVO [15,16], and that the mean vascular leaking area in the retina was larger in BRVO patients with SRF than in patients without SRF [15]. Park et al also showed that the mean aqueous levels of VEGF were significantly higher in BRVO eyes with SRF than in eyes with cystoid ME without additional SRF [15] .…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion

Hoeh

Ruppenstein

Ach

et al. 2010

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 97%

OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion

Hoeh

Ruppenstein

Ach

et al. 2010

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…[3][4][5][6][7] Several recent studies have reported that VEGF has an important role in the pathophysiology of ME by inducing blood-retinal barrier breakdown and increasing vascular permeability. [6][7][8][9] Elevated VEGF level in vitreous has been reported in patients with BRVO, and this elevation was correlated with the severity of ME and area of non-perfusion. 7 These correlations prompted interest in the use of pharmacologic inhibition of VEGF for treatment of ME.…”

Section: Introductionmentioning

confidence: 97%

Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion

Moon

Kim

Sagong

2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate efficacy and safety of combination therapy of intravitreal bevacizumab (IVB) with single simultaneous posterior subtenon triamcinolone acetonide (STA) for treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Methods This was a prospective, randomized, interventional comparative study conducted in 45 eyes with ME secondary to BRVO who were treated primarily with IVB 1.25 mg (23 eyes, IVB group) or combination therapy of IVB 1.25 mg with a single simultaneous STA 40 mg (18 eyes, IVB/STA group). Reinjections were performed with IVB if optical coherence tomography (OCT) showed recurrent ME associated with decreased visual acuity. The main outcome measurement was the number of additional IVB injections, and changes of best-corrected visual acuity (BCVA) and central macular thickness (CMT) during a 6-month follow-up period were compared. Results BCVA showed significant improvement in two groups at 6 months. In addition, CMT showed significant decrease in two groups at 6 months. No significant differences in the change of BCVA and CMT at 6 months after injection (P = 0.973, P = 0.639) were observed between the two groups. A statistically significant difference was found regarding the number of additional IVB injections (IVB group 0.96 ± 0.83; IVB/STA group 0.44 ± 0.70, P = 0.034).Conclusion Although combination therapy of IVB with a single simultaneous STA for treatment of ME secondary to BRVO did not affect the visual outcomes compared with IVB monotherapy, it had a benefit of reducing the number of additional IVB injections.

show abstract

“…In general, the data indicate that levels of VEGF in the aqueous are lower than that in the vitreous. Control levels of VEGF measured in subjects who had surgery to remove cataracts ranged 50-112 pg/ml [40,45]. The highest levels of VEGF were found in the aqueous of patients with active disease such as wet age-related macular degeneration (AMD), PDR, and diffuse macular edema (DME).…”

Section: Evidence For Vegf As a Biomarker In Aqueous Humormentioning

confidence: 99%

“…In 6 of the studies, samples were obtained from patients who were already undergoing minimally invasive intravitreal injections of bevacizumab (Avastin, Genentech, South San Francisco, CA) or triamcinolone [40,[42][43][44][45][46]. Remarkably, none of the studies in this survey involved subjects who were injected with ranibizumab or pegaptanib.…”

Section: Evidence For Vegf As a Biomarker In Aqueous Humormentioning

confidence: 99%

Validation of Molecular and Genomic Biomarkers of Retinal Drug Efficacy: Use of Ocular Fluid Sampling to Evaluate VEGF

Sharma

Rowe-Rendleman²

2010

Neurochem Res

View full text Add to dashboard Cite

The use of tissue- and cell-based methods in developing drugs for retinal diseases is inefficient. Consequently, many aspects of ocular drug therapy for retinal diseases are poorly understood. Biomarkers as prognostic indicators of change are needed to optimize the use of drugs. VEGF is considered an important target of drug therapy and VEGF levels in tissue are indicative of solid tumor growth. However, since many aspects of VEGF as a biomarker of ocular disease have not been validated, it has been difficult to ascertain without invasive procedures whether VEGF in the eye is a biomarker of response to drug therapy. Using published papers, registered clinical trials, and proteomic databases we assessed the earlier evidence for VEGF as an exploratory biomarker of proliferative and vasculopathic disease of the retina and asked whether the molecule has been rigorously validated in clinical trials. The emerging use of aqueous humor sampling has made it possible to explore biomarkers in oculo, and determine whether they are predictive of drug efficacy. We present data supporting the use of aqueous humor to validate drug-signaling pathways and biomarkers in the eye. In addition, we recommend convening a collaborative congress to help standardize the identification, validation, and use of biomarkers in retinal disease.

show abstract

Aqueous Vascular Endothelial Growth Factor Levels Are Associated With Serous Macular Detachment Secondary to Branch Retinal Vein Occlusion

Abstract: Our results indicate that excessive increase in vascular permeability because of VEGF upregulation may contribute to the development of SRD secondary to branch retinal vein occlusion.

Cited by 47 publications

References 21 publications

OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion

OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion

Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion

Validation of Molecular and Genomic Biomarkers of Retinal Drug Efficacy: Use of Ocular Fluid Sampling to Evaluate VEGF

Contact Info

Product

Resources

About